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Abstract
Background: Extended Spectrum Beta- Lactamase producing organisms causing urinary tract infections (ESBL-UTI)
are increasing in incidence and pose a major burden to health care. While ESBL producing Klebsiella species seem
to account for most nosocomial outbreaks, ESBL-producing E. coli have been isolated from both hospitalized and
non-hospitalized patients. Although 95-100% ESBL organisms are still considered sensitive to meropenem, rapid
emergence of carbapenem resistance has been documented in many countries. The objective of this study was to
evaluate urinary tract infections caused by ESBL producers and the antibiotic susceptibility patterns in Sri Lanka.
Methods: Patients with confirmed ESBL-UTI admitted to Professorial Medical Unit, Colombo North Teaching
Hospital from January – June 2015 were recruited to the study. Their urine culture and antibiotic susceptibility
reports were evaluated after obtaining informed written consent.
Results: Of 61 culture positive ESBL-UTIs, E. coli caused 53 (86.8%), followed by Klebsiella in 8 (13.1%).30 (49.1%) had
a history of hospitalization within the past three months and included 6/8(75%) of Klebsiella UTI and 24/53(45.2%)
of E.coli UTI. Antibiotic susceptibility of ESBL organisms were; Meropenem 58 (95%), Imipenem 45 (73.7%), Amikacin
37 (60.6%) and Nitrofurantoin 28(45.9%). In 3(4.9%), E.coli were resistant to Meropenem. These three patients had
received multiple antibiotics including meropenem in the recent past for recurrent UTI.
Conclusions: We observed a higher percentage of E. coli over Klebsiella as ESBL producing organisms suggesting
most ESBL-UTIs to be community acquired, Carbapenems seem to remain as the first line therapy for majority of
ESBL-UTIs in the local setting. However 4.9% prevalence of meropenem resistance is alarming compared to other
countries.
Although prior antibiotic utilization and hospitalization may contribute to emergence of ESBL producing Klebsiella
and E.coli in Sri Lanka, high prevalence of community acquired ESBL-E. coli needs further investigations to identify
potential causes . Being a third world country with a free health care system, observed alarming rate of carbapenem
resistance is likely to add a significant burden to health budget. We feel that treatment of infections in general needs a
careful approach adhering to recommended antibiotic guidelines in order to prevent emergence of multi drug
resistant organisms.
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Background
Infections caused by extended spectrum beta-lactamase
(ESBL)-producing organisms are rising in epidemic pro-
portions and poses a threat and a challenge to clinical
practice around the World [1]. Although the exact global
prevalence of ESBL producing organisms is not known,
certain studies in the Indian subcontinent have found
nearly 50% prevalence [2, 3].
ESBLs are a group of plasmid-mediated, diverse, com-
plex and rapidly evolving enzymes which are capable of
hydrolyzing penicillins, broad-spectrum cephalosporins
and monobactams [1]. While ESBLs are generally de-
rived from TEM and SHV-type enzymes, CTX –M type
enzyme isolated from ESBL producers had been recog-
nized as an important subtype leading to multi drug re-
sistance [4]. ESBLs are commonly produced by E. coli
and Klebsiella species [1]. The plasmids bearing genes-
encoding ESBLs also frequently carry genes that encode
resistance to other antimicrobial agents, such as amino-
glycosides and quinolones [5]. Therefore, the selection
of antibacterials against ESBL organisms in clinical prac-
tice is often complicated.
Infections caused by ESBL producing organisms range
from uncomplicated urinary tract infections (UTIs) to
life-threatening sepsis. Fluoroquinolones may be used
for the treatment of uncomplicated UTIs when found
susceptible, but emerging resistance has limited their
role in todays’ clinical practice [5]. Therefore, carbapen-
ems are regarded as the drugs of choice in the treatment
of severe infections caused by ESBL-producing organ-
isms [5]. However carbapenem resistance has also been
increasingly reported in many countries recently [5].
Therefore, antibiotic therapy of infections caused by
ESBL producers including that of UTIs is challenging.
The options of antibiotics are very limited, and require
long term treatment with novel and costly antibiotics
such as Fosfomycin and Colistin. Risk factors for urinary
tract infections caused by ESBL producers include recent
hospitalizations, recent antibiotic treatment, age over
60 years, diabetes, male gender, recent Klebsiella pneumo-
niae infection, previous use of second or third-generation
cephalosporins, quinolones, and penicillins [6].
In Sri Lanka the ESBL producing organisms and their
antibiotic susceptibility patterns have not been exten-
sively studied. We conducted a hospital based study in
order to identify the ESBL producing organisms and
their antibiotic susceptibility patterns using patients di-
agnosed with ESBL-UTI.
Methods
A descriptive cross-sectional study was conducted over a
period of six months among adult patients admitted to
the Professorial Medical Unit of the Colombo North
Teaching Hospital, Ragama, Sri Lanka. Consecutive
adult patients who had a culture positive urinary tract
infections caused by ESBL producers admitted during
the study period fulfilled criteria for selection to the
study. (Figure 1: Flow chart on recruitment of study par-
ticipants) Of them urine cultures that had been per-
formed in five selected private hospital laboratories that
maintain quality control and function under the supervi-
sion of consultant microbiologists were selected. Patients
who consented to provide demographic, clinical and la-
boratory data were enrolled for the study. In these se-
lected laboratories, ESBL organisms were detected using
CLSI or Stokes Disc Diffusion Techniques and carba-
penem resistance among ESBL organisms were reported
based on the diameter of the zone of inhibition. None of
the laboratories routinely performed the modified Hodge
test for this purpose. Severity assessment of patients
were carried out using clinical parameters (fever
>1000 F, presence of chills, rigors, renal angle tenderness,
reduced urine output) and laboratory parameters (white
cell count > 11,000/mm3 with neutrophil predominance,
high CRP, high serum creatinine and ultrasound evi-
dence of acute parenchymal renal disease or pyeloneph-
ritis). Blood cultures were obtained from all severely ill
patients based on management protocol for severe py-
elonephritis or septicemia. Selections of antibiotics for
the treatment of these patients were based on the anti-
biotic susceptibility patterns documented in the urine
culture reports. Ethical clearance was obtained from the
Fig. 1 Flow chart on recruitment of study participants
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Ethics Review Committee, Faculty of Medicine, University
of Kelaniya. Informed written consent was obtained from
the patients prior to recruitment. The demographic and
relevant clinical data was collected and recorded in a pre-
tested interviewer administered questionnaire. Informa-
tion related to past medical history, use of antibiotics and
hospitalizations were collected from patients’ follow up
medical records. Relevant investigation results and data
on treatment during current admission were obtained
from ward bed head tickets (in ward patient management
records). Data analysis was done using the SPSS software
package (IBM Corporation, NY).
Results
Total of 61 patients consented for the study. Of the 61,
30 (49.1%) were male patients and the mean (SD) age
was 64.1(12.6) years. E.coli accounted for 53(86.8%) of
ESBL UTI’s and Klebsiella was found in the rest 8
(13.1%). (Table 1) Thirty nine (63.9%) had received anti-
biotics in the past three months (11 were on prophylac-
tic antibiotics);23(37.7%) penicillins (Amoxycillin and
co-amoxyclav), 18 (29.5%) 3rd generation cephalospo-
rins, 17 (27.8%) 2nd generation cephalosporins and 18
(29.5%) fluoroquinolones (Ciprofloxacin, Norfloxacin
and levofloxacin). They included all 8 (100%) patients
who had Klebsiella UTI and 31/53 (58.4%) who had UTI
caused by E. coli. Of 61 patients, 30 (49.1%) had a his-
tory of hospitalization within the past three months and
included 6/8(75%) of Klebsiella UTI and 24/53 (45.2%)
of E.coli UTI (Table 2). Of the study population, 28 pa-
tients had blood cultures performed and of which 8 were
bacteremic and had the same organism found in urine
grown in the blood cultures.
With regards to antibiotic susceptibility (Table 3), ma-
jority of ESBL organisms were susceptible to carbapen-
ems; 58(95%) to Meropenem and 45(73.7%) to
Imipenem, and 37(60.6%) were sensitive to Amikacin
and 28(45.9%) to Nitrofurantoin. Therefore, resistance to
Meropenem was found in 3 (4.9%) and to Imipenem in
16(26.2%). The three patients who had meropenem re-
sistance had previously received multiple antibiotics in-
cluding carbapenems for recurrent urinary tract
infections and all three of them had diabetes. Two of
these isolates were susceptible to amikacin and the other
showed susceptibility to Piparacillin-tazobactum. All
these patients were treated with respective antibiotics
until they had a normal CRP level and required treat-
ment for at least 10-14 days. All study participants had a
repeat urine culture one month after the completion of
treatment and remained negative for any growth.
Discussion
In this preliminary hospital based study, our objective
was to identify the organisms causing ESBL-UTIs and
their antibiotic susceptibility pattern. Therefore our
study does not address issues such as incidence and
prevalence of ESBL-UTI in the country. All of these pa-
tients had a special reference for admission to the unit,
mainly based on non-availability or non- affordability of
Table 1 Characteristics of the study population
Gender Male 30 (49.1%)
Female 31 (50,8%)





Bronchial Asthma 8 (13.1%)
Chronic Liver Disease 10 (16.3%)
Renal Stones 3 (4.9%)
USS findings
Acute pyelonephritis 21 (34.4%)




Table 2 Associations with ESBL UITs
Associated factors Yes (%) No (%)
On Prophylactic Antibiotics 11 (18.0%) 50 (81.9%)
Hospitalization in last 3 months 30 (49.1%) 31 (50.8%)
Antibiotic treatment in last 3 months 39 (63.9%) 22 (36.0%)
Previous use of penicillin
(Amoxycillin/co-amoxyclav)
23 (37.7%) 38 (62.2%)
Previous use of fluoroquinolones
(Ciprofloxacin/Levofloxacin)
18 (29.5%) 43 (70.4%)
Previous use of 2G cephalosporins 17 (27.8%) 44 (72.1%)
Previous use of 3G cephalosporins 18 (29.5%) 43 (70.4%)
Table 3 Antibiotic sensitivity pattern
Antibiotic Yes No
Meropenem 58 (96.1%) 3 (4.9%)
Imipenum 45 (73.7%) 16 (26.2%)
Nitrofurantoin 28 (45.9%) 33 (54%)
Amikacin 37 (60.6%) 24 (39.3%)
Gentamycin 30 (49.1%) 31 (50.8%)
Ceftrioxone 0 61 (100%)
Ceftazidime 0 61 (100%)
Ciprofloxacin 6 (9.8%) 55 (90.1%)
Piparacillin-tazobactum 12 (19.6%) 49 (80.3%)
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expensive antibiotics or were considered too compli-
cated for the management in peripheral hospitals.
In this study, majority (86.2%) of the ESBL producing
isolates were E.coli and only 13.8% were Klebsiella. Simi-
lar pattern was found in South India in 2010 and a re-
versed pattern was found in North India in 2013 [3, 7].
Although we observed a higher percentage of E. coli over
Klebsiella as ESBL producing organisms, it is difficult to
conclude that most ESBLs in Sri Lanka are due to E.
coli. This is because this study has a patient selection
bias. Furthermore, ESBL-producing Klebsiella species
are considered responsible for most nosocomial out-
breaks and they are usually clonal and the strains are
known to spread mainly through cross-transmission [2].
There is no evidence that hospital-acquired ESBL-
producing Klebsiellae are decreasing in importance. Data
from the Centers for Disease Control and Prevention
show 47% increase of Klebsiella pneumoniae isolates
from United States intensive care units in 2003 com-
pared with the preceding 5 years [8]. On the other hand,
an increase in the number of ESBL-producing E. coli is
being described in several parts of the world [9–12]. In
contrast to ESBL Klebsiella infections, many of the
ESBL-producing E. coli have been isolated from non-
hospitalized patients [9–12], and were less frequently
clonally related and found to produce CTX-M enzymes
[9–12]. These chromosomally encoded enzymes were
found in some environmental bacteria, such as Kluyvera
species [13], that colonize in farm animals [14, 15], and
subsequently in a significant proportion of people in the
community [16, 17]. In a study carried out in Netherlands
ESBL producing E. coli were found in meat and poultry
and were similar to strains isolated in rectal swabs and
blood cultures of patients with ESBL sepsis, suggesting
transmission of ESBL through the food chain [18]. Fur-
thermore, some patients with infections caused by ESBL-
producing Enterobacteriaceae did not have any previous
significant health care contact suggesting they acquired
ESBL producing E coli in the community. Similarly, in our
study, we found 75% patients with Klebsiella ESBL had
hospitalization and 100% of them were treated with an
antibiotic during past three months compared to only
49% with E coli UTI had hospital admissions and 58% re-
ceived antibiotics. This may suggest that patients with
Klebsiella ESBL would have been nosocomial in origin
and majority of E. coli would have been community ac-
quired. However, this speculation needs confirmation by
genetic studies.
In this cohort of patients with ESBL UTIs, 39 (63.9%)
had received antibiotics during the three months prior to
admission and out of the antibiotics received, penicillin
group (amoxicillin and co-amoxyclav) was the commonest
followed by 2nd generation cephalosporins, 3rd gener-
ation cephalosporins and fluoroquinolones (ciprofloxacin,
levofloxacin and norfloxacin) similar to that had been doc-
umented in other studies [2, 19]. Furthermore, 11(18%)
were on prophylactic antibiotics for recurrent urinary tract
infections and they developed ESBL-UTI while on antibi-
otics. Today, use of prophylactic antibiotics in recurrent
urinary tract infections is no longer recommended as it
enhances emergence of resistant strains [20]. Although
whether use of prophylactic antibiotic per se, is a risk fac-
tor for emergence of ESBL producers is not clear [21],
past use of antibiotics has been previously described in
association with emergence of ESBL producers [6, 22].
Furthermore, inappropriate use of antimicrobials has
been shown to play a pivotal role in the emergence of
multi drug resistant organisms. Selection of resistant
forms can occur during or after such antimicrobial
treatment. In addition, surface antibacterials that are
used for disinfection of many household products may
play a role in development of antibacterial resistance
[23]. Therefore clinicians should ensure the use of appro-
priate antibiotics for recommended periods in adequate
doses in order to prevent emergence of multidrug resist-
ant organisms such as ESBLs.
Furthermore, hospitals should implicate strategies to
minimize the spread of ESBL producing organisms by
observing universal precautions and minimizing contact
among hospitalized patients [24]. This might reduce the
spread of ESBL producing organisms in the community.
Siegel et al recommended that patients infected with
multi drug resistant organisms should have restricted
contact with other patients [24]. Therefore, although it
can be controversial, early discharge of not so seriously
ill patients, such as those with ESBL UTIs, with view to
home based treatment with potent and effective antibi-
otics which can be introduced once a day such as Erta-
penem [25] or aminoglycosides such as amikacin may be
considered in order to prevent spread of ESBL organ-
isms within institutions. Furthermore, adherence to rec-
ommended hand washing techniques or use of hand
rubs may help to prevent transmission of these infec-
tions from one patient to the other [26].
The carbapenems (imipenem, meropenem, ertapenem,
doripenem) are still the first choice of treatment for ser-
ious infections with ESBL-producing E. coli and K. pneu-
moniae. It has been reported that >98% of the ESBL-
producing E. coli, K. pneumonia and P. mirabilis are still
susceptible to these drugs [27]. But with the emergence
of the carbapenem-resistant Enterobacteriaceae, some
older drugs were found effective against ESBL-producing
E. coli or K. pneumonia infections. Fosfomycin was re-
ported of having in vitro activity against the ESBL-
producing E. coli or K. pneumoniae. In Hong Kong,
most of the ESBL-producing E. coli isolates were re-
ported to be sensitive to fosfomycin [28]. Colistin, Tige-
cycline, Polymyxins and some aminoglycosides are
Fernando et al. BMC Infectious Diseases  (2017) 17:138 Page 4 of 6
considered effective in the treatment of carbapenem re-
sistant organisms [27]. The role of aminoglycosides should
not be forgotten as some species will be sensitive and re-
spond to aminoglycoside therapy. In a Spanish study pub-
lished in 2014, 50 cases of Carbapenem resistant
Klebsiella infections were treated with aminoglycosides
showing a statistically significant reduction in mortality
[29]. The role of piperacillin-tazobactam (PTZ) for pa-
tients infected with ESBL-producing pathogens remains
unclear. Although ESBLs are generally inhibited by tazo-
bactam, many organisms produce multiple ESBLs simul-
taneously, which may reduce the effectiveness of PTZ
[30]. In a study done by Tamma et al in 2015 found PTZ
to be inferior to carbapenem therapy for the treatment of
ESBL bacteremia and suggested early carbapenem therapy
for patients at high risk of invasive ESBL infections [31].
In this study, 95% of ESBL organisms were sensitive to
meropenem. However one crucial finding of this prelimin-
ary study was the3/61 (4.9%) prevalence of meropenem
resistance among ESBL organisms. All these three patients
were diabetics and had a history of recurrent urinary tract
infections with multiple hospitalizations and received
multiple antibiotics including meropenem. Although lit-
erature on carbapenem resistant ESBL producers is lim-
ited, available regional studies demonstrate substantially
lower rates of carbapenem resistance. No carbapenem re-
sistance has been documented in India among 167 pa-
tients in 2014 [19] and in Bangladesh among 115 patients
in 2008 [32]. However, 0.4% carbapenem resistance has
been documented in Pakistan in 2007 [33].
Conclusions
E. coli and Klebsiella were found to be the main ESBL-
UTI among the patients referred for further management
in the study setting and occurrence of carbapenem resist-
ance was observed within them. Although most ESBL-
UTIs had an association with past hospitalization and
antibiotic use similar to that is documented in other coun-
tries, its significance needs to be confirmed with a proper
control group. Occurrence of community acquired ESBL-
UTI needs further study to identify the likely reasons and
the sources of such infections. Sri Lanka, being a third
world country with a free health care system, presence of
infections caused by ESBL producers and occurrence of
carbapenem resistance among them is likely to add a sig-
nificant burden to health budget. We feel that treatment
of infections in general needs a careful approach and
stress upon the value of adherence to recommended anti-
biotic guidelines in order to prevent emergence of multi
drug resistant organisms. Furthermore, antibiotics for
meropenem resistant ESBL producers such as Fosfomycin
and Colistins should be made available while reserving
them only for the treatment of life threatening infections
caused by ESBL producers.
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